Zevalin
·
- Prescription status not stated
- Everything that fits nowhere else, such as contrast media
- Active substance
- Ibritumomab tiuxetan
- Made by
- Ceft Biopharma s.r.o.
- Source
- Official label
Quoted from the official source. Not yet reviewed by Mediclarum — the leaflet in your pack is authoritative.
What it is for
- Zevalin is indicated in adults. [90Y]-radiolabelled Zevalin is indicated as consolidation therapy after remission induction in previously untreated patients with follicular lymphoma. The benefit of Zevalin following rituximab in combination with chemotherapy has not been established. [90Y]-radiolabelled Zevalin is indicated for the treatment of adult patients with rituximab relapsedorrefractory CD20+ follicular B-cell non-Hodgkin's lymphoma (NHL).
From the official label · 2026-09-30 · European Medicines Agency
Same active substance, strength and form in other countries
Matched on active substance, strength and kind of form only. This is not a statement that the products are equivalent or interchangeable: other ingredients, release and approved uses can differ — ask a pharmacist before swapping.
Medicine passport: one printable page to show a pharmacist abroad
United StatesNo exact match for this strength and form
SpainNo exact match for this strength and form
Details
| Made by | Ceft Biopharma s.r.o. |
|---|---|
| Active substance | Ibritumomab tiuxetan |
| Used in | Everything that fits nowhere else, such as contrast media |
| Classification | V10XX02 · Everything that fits nowhere else, such as contrast media |
| Authorised on | 2004-01-16 |
| Last updated by the regulator | 2024-07-10 |
| EMA product number | EMEA/H/C/000547 |
Source: European Medicines Agency — medicine data · 2026-09-30 · not reviewed by a clinician
Source: European Medicines Agency (EMA). Product information as published by EMA. Reuse terms: EMA legal notice (reproduction authorised).